Enzo Biochem Stock Buy Hold or Sell Recommendation
| ENZ Stock | USD 1.08 0.05 4.85% |
Considering the 90-day investment horizon and your above-average risk tolerance, our recommendation regarding Enzo Biochem is 'Strong Hold'. A buy or sell recommendation provided by Macroaxis is an automated directive regarding whether to purchase or sell Enzo Biochem given historical horizon and risk tolerance towards Enzo Biochem. When Macroaxis issues a 'buy' or 'sell' recommendation for Enzo Biochem, the advice is generated through an automated system that utilizes algorithms and statistical models.
Check out Enzo Biochem Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. For more information on how to buy Enzo Stock please use our How to Invest in Enzo Biochem guide. In addition, we conduct extensive research on individual companies such as Enzo and provide practical buy, sell, or hold advice based on investors' investing horizon and their risk tolerance towards Enzo Biochem. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
Enzo |
Execute Enzo Biochem Buy or Sell Advice
The Enzo recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Enzo Biochem. Macroaxis does not own or have any residual interests in Enzo Biochem or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Enzo Biochem's advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Strong Hold
Market Performance | Very Weak | Details | |
Volatility | Moderately volatile | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Slowly supersedes the market | Details | |
Investor Sentiment | Interested | Details | |
Analyst Consensus | Strong Sell | Details | |
Financial Strenth (F Score) | Healthy | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Enzo Biochem Trading Alerts and Improvement Suggestions
| Enzo Biochem has some characteristics of a very speculative penny stock | |
| The company reported the last year's revenue of 31.91 M. Reported Net Loss for the year was (26.08 M) with profit before taxes, overhead, and interest of 11.57 M. | |
| Enzo Biochem has about 82.37 M in cash with (26.26 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.44. | |
| Roughly 24.0% of the company shares are held by company insiders |
Enzo Biochem current analysts advice
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Enzo analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Enzo analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
The consensus estimates and target price estimation comprises individual analyst assessments, and may or may not mutch the Macroaxis buy or sell advice. It is determined by taking an average of all analyst recommendations and classifying them as Strong Buy, Buy, Hold, or Sell.
Enzo Biochem Returns Distribution Density
The distribution of Enzo Biochem's historical returns is an attempt to chart the uncertainty of Enzo Biochem's future price movements. The chart of the probability distribution of Enzo Biochem daily returns describes the distribution of returns around its average expected value. We use Enzo Biochem price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Enzo Biochem returns is essential to provide solid investment advice for Enzo Biochem.
| Mean Return | -0.0001 | Value At Risk | -1.94 | Potential Upside | 2.97 | Standard Deviation | 1.73 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Enzo Biochem historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Enzo Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument, such as Enzo Biochem, soars without any apparent reason? This usually happens because many institutional investors are aggressively trading Enzo Biochem back and forth among themselves.
| Shares | Bbr Partners, Llc | 2024-09-30 | 100 K | Nierenberg Investment Management Co | 2024-09-30 | 88.6 K | Northern Trust Corp | 2024-09-30 | 67.2 K | Lazard Asset Management Llc | 2024-06-30 | 50.5 K | T. Rowe Price Associates, Inc. | 2024-06-30 | 44.8 K | Xtx Topco Ltd | 2024-09-30 | 34.4 K | Citadel Advisors Llc | 2024-09-30 | 26.6 K | Kempner Capital Management Inc | 2024-09-30 | 25.5 K | Millennium Management Llc | 2024-06-30 | 19.4 K | Harbert Fund Advisors Inc | 2024-09-30 | 5.2 M | Renaissance Technologies Corp | 2024-09-30 | 2.5 M |
Enzo Biochem Cash Flow Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change To Inventory | 85K | (4.9M) | (2.7M) | (334K) | 1.1M | 1.1M | |
| Change In Cash | (12.3M) | (34.3M) | 8.3M | 60.8M | (31.0M) | (29.5M) | |
| Free Cash Flow | (19.3M) | (4.0M) | (20.1M) | (39.7M) | (26.8M) | (25.5M) | |
| Depreciation | 2.8M | 2.7M | 2.8M | 2.7M | 1.3M | 1.2M | |
| Other Non Cash Items | (1.2M) | (7.0M) | 3.3M | (75.8M) | 4.5M | 4.7M | |
| Capital Expenditures | 2.2M | 4.4M | 3.5M | 2.8M | 545K | 517.8K | |
| Net Income | (28.5M) | 7.9M | (18.3M) | 20.3M | (26.1M) | (24.8M) | |
| End Period Cash Flow | 48.6M | 14.3M | 22.6M | 83.4M | 52.4M | 41.6M | |
| Change To Netincome | 11.3M | (5.4M) | 1.7M | (78.5M) | (70.7M) | (67.1M) | |
| Investments | (2.2M) | (34.5M) | 28.7M | 99.0M | (545K) | (517.8K) | |
| Net Borrowings | 7.0M | (339K) | (269K) | (1.1M) | (1.3M) | (1.2M) |
Enzo Biochem Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Enzo Biochem or Health Care Providers & Services sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Enzo Biochem's price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Enzo stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | -0.05 | |
β | Beta against Dow Jones | 0.32 | |
σ | Overall volatility | 1.83 | |
Ir | Information ratio | -0.07 |
Enzo Biochem Volatility Alert
Enzo Biochem exhibits very low volatility with skewness of 0.84 and kurtosis of 1.28. Enzo Biochem is a potential penny stock. Although Enzo Biochem may be in fact a good instrument to invest, many penny stocks are speculative in nature and are subject to artificial price hype. Please make sure you totally understand the upside potential and downside risk of investing in Enzo Biochem. We encourage investors to look for signals such as email spams, message board hypes, claims of breakthroughs, volume upswings, sudden news releases, promotions that are not reported, or demotions released before SEC filings. Please also check biographies and work history of current and past company officers before investing in high volatility instruments, penny stocks, or equities with microcap classification. You can indeed make money on Enzo instrument if you perfectly time your entry and exit. However, remember that penny stocks that have been the subject of artificial hype usually unable to maintain their increased share price for more than just a few days. The price of a promoted high volatility instrument will almost always revert back. The only way to increase shareholder value is through legitimate performance backed up by solid fundamentals.Enzo Biochem Fundamentals Vs Peers
Comparing Enzo Biochem's fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Enzo Biochem's direct or indirect competition across all of the common fundamentals between Enzo Biochem and the related equities. This way, we can detect undervalued stocks with similar characteristics as Enzo Biochem or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Enzo Biochem's fundamental indicators could also be used in its relative valuation, which is a method of valuing Enzo Biochem by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Enzo Biochem to competition |
| Fundamentals | Enzo Biochem | Peer Average |
| Return On Equity | -0.15 | -0.31 |
| Return On Asset | -0.0744 | -0.14 |
| Profit Margin | (0.82) % | (1.27) % |
| Operating Margin | (0.39) % | (5.51) % |
| Current Valuation | 4.95 M | 16.62 B |
| Shares Outstanding | 52.24 M | 571.82 M |
| Shares Owned By Insiders | 23.72 % | 10.09 % |
| Shares Owned By Institutions | 32.04 % | 39.21 % |
| Number Of Shares Shorted | 432.99 K | 4.71 M |
| Price To Earning | 26.60 X | 28.72 X |
| Price To Book | 0.96 X | 9.51 X |
| Price To Sales | 1.69 X | 11.42 X |
| Revenue | 31.91 M | 9.43 B |
| Gross Profit | 11.57 M | 27.38 B |
| EBITDA | (8.35 M) | 3.9 B |
| Net Income | (26.08 M) | 570.98 M |
| Cash And Equivalents | 82.37 M | 2.7 B |
| Cash Per Share | 0.44 X | 5.01 X |
| Total Debt | 3.51 M | 5.32 B |
| Debt To Equity | 0.38 % | 48.70 % |
| Current Ratio | 2.21 X | 2.16 X |
| Book Value Per Share | 1.07 X | 1.93 K |
| Cash Flow From Operations | (26.26 M) | 971.22 M |
| Short Ratio | 3.94 X | 4.00 X |
| Earnings Per Share | (0.19) X | 3.12 X |
| Target Price | 5.5 | |
| Number Of Employees | 125 | 18.84 K |
| Beta | 0.73 | -0.15 |
| Market Capitalization | 53.81 M | 19.03 B |
| Total Asset | 85.76 M | 29.47 B |
| Retained Earnings | (294.43 M) | 9.33 B |
| Working Capital | 45.24 M | 1.48 B |
| Current Asset | 91.4 M | 9.34 B |
Note: Acquisition by Wolf James G. of 5000 shares of Enzo Biochem at 2.14 subject to Rule 16b-3 [view details]
Enzo Biochem Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Enzo . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About Enzo Biochem Buy or Sell Advice
When is the right time to buy or sell Enzo Biochem? Buying financial instruments such as Enzo Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Enzo Biochem in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Hotels Thematic Idea Now
Hotels
Hotels, inns, motels, and other companies providing lodging and hospitality services. The Hotels theme has 39 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Hotels Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for Enzo Stock Analysis
When running Enzo Biochem's price analysis, check to measure Enzo Biochem's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Enzo Biochem is operating at the current time. Most of Enzo Biochem's value examination focuses on studying past and present price action to predict the probability of Enzo Biochem's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Enzo Biochem's price. Additionally, you may evaluate how the addition of Enzo Biochem to your portfolios can decrease your overall portfolio volatility.